Tango Therapeutics, Inc. TNGX
24.30 USD +1.56 (+6.86%)
At closeNov 10, 2026, 4:52 PM EST
24.30 0.00 0.00%
After hours · Nov 10, 4:52 PM ET
22.38 Day range 24.65
7.49 52-week range 34.39
- YTD
- +174.27%
- 1 year
- +206.43%
News
benzinga.com JP Morgan Maintains Overweight on Tango Therapeutics, Raises Price Target to $47 JP Morgan analyst Brian Cheng maintains Tango Therapeutics (NASDAQ:TNGX) with a Overweight and raises the price target from $46 to $47.
benzinga.com Wedbush Maintains Outperform on Tango Therapeutics, Lowers Price Target to $40 Wedbush analyst Robert Driscoll maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and lowers the price target from $45 to $40.
benzinga.com HC Wainwright & Co. Maintains Buy on Tango Therapeutics, Lowers Price Target to $67 HC Wainwright & Co. analyst Robert Burns maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and lowers the price target from $68 to $67.
benzinga.com Tango Therapeutics Q3 EPS $(0.39) Misses $(0.35) Estimate Tango Therapeutics (NASDAQ:TNGX) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.35) by 11.43 percent. This is a 378.57 percent decrease over…
globenewswire.com Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015 BOSTON and SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to delivering breakthrough targeted therapies that…
globenewswire.com Tango Therapeutics to Participate in Guggenheim's 3rd Annual Healthcare Innovation Conference BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced that Malte Peters, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to…- benzinga.com HC Wainwright & Co. Reiterates Buy on Tango Therapeutics, Maintains $68 Price Target HC Wainwright & Co. analyst Robert Burns reiterates Tango Therapeutics (NASDAQ:TNGX) with a Buy and maintains $68 price target.
benzinga.com Crude Oil Surges 4%; SLB Shares Jump Following Upbeat Q3 Earnings U.S. stocks fell Friday: Dow -1.12%, S&P 500 -0.43%, Nasdaq -0.13%. Energy and oil rose; SLB gained 7% on strong results.
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data? Tango Therapeutics reports an 82% response rate in pancreatic cancer trials and prepares a randomized registrational study for early 2027.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 29.7% to $0.42 during Friday's pre-market session. The company's market cap stands at $63.6 million. Electra Therapeutics (NASDAQ:ETRA)…- benzinga.com Tango Therapeutics Announces Results From Ongoing Phase 1/2 Study Of Vopimetostat In Combination With Daraxonrasib In Patients With Metastatic Pancreatic Ductal Adenocarcinoma And Non-Small Cell Lung Cancer; Study Demonstrated 82% Objective Response Rate, Median PFS Not Yet Reached, And 9M PFS Rate Of 88%, In 22 Patients Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to delivering breakthrough targeted therapies that extend and improve the lives of patients with cancer, today…
benzinga.com Winnebago Industries Posts Upbeat Q4 Earnings, Joins SpaceX, Super Micro Computer And Other Big Stocks Moving Higher On Wednesday U.S. stocks were mixed as the Dow gained 400 points. Winnebago jumped 7% on an EPS beat, while Super Micro and SpaceX rallied on strong outlooks.- benzinga.com William Blair Initiates Coverage On Tango Therapeutics with Outperform Rating William Blair analyst Alethia Young initiates coverage on Tango Therapeutics (NASDAQ:TNGX) with a Outperform rating.
- benzinga.com Tango Therapeutics To Present Updated Data From Phase 1/2 Study Of Vopimetostat In Combination With Daraxonrasib Or Zoldonrasib In Patients With MTAPdel/RASmut Metastatic PDAC And NSCLC At ESMO Congress 2026 Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the…
benzinga.com Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving Higher On Wednesday U.S. stocks fell, but Caleres surged 14% on strong results and higher guidance. Opus Genetics, Signet and Oddity also posted big gains.
benzinga.com HC Wainwright & Co. Maintains Buy on Tango Therapeutics, Raises Price Target to $68 HC Wainwright & Co. analyst Robert Burns maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and raises the price target from $66 to $68.
benzinga.com Guggenheim Maintains Buy on Tango Therapeutics, Raises Price Target to $35 Guggenheim analyst Michael Schmidt maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and raises the price target from $32 to $35.- benzinga.com Tango Therapeutics Files Prospectus For Up To $400M Common Stock Offering Up to $400,000,000Common StockWe have previously entered into a Sales Agreement, or the sales agreement, with Leerink Partners LLC, or Leerink Partners, dated November 21, 2025, relating to the sale…
benzinga.com Tango Therapeutics Q2 EPS $(0.37) Misses $(0.32) Estimate Tango Therapeutics (NASDAQ:TNGX) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.32) by 15.62 percent. This is a 5.71 percent decrease over losses of…- benzinga.com Mizuho Maintains Outperform on Tango Therapeutics, Raises Price Target to $40 Mizuho analyst Joseph Catanzaro maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and raises the price target from $36 to $40.
benzinga.com This Veracyte Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Wall Street analysts initiated coverage on various top stocks, including VCYT, UMAC, FISN, LTRX, and TNGX with positive ratings and price targets.
benzinga.com JP Morgan Initiates Coverage On Tango Therapeutics with Overweight Rating, Announces Price Target of $46 JP Morgan analyst Brian Cheng initiates coverage on Tango Therapeutics (NASDAQ:TNGX) with a Overweight rating and announces Price Target of $46.- benzinga.com Canaccord Genuity Maintains Buy on Tango Therapeutics, Raises Price Target to $46 Canaccord Genuity analyst John Newman maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and raises the price target from $42 to $46.
- benzinga.com Jefferies Upgrades Tango Therapeutics to Buy, Raises Price Target to $60 Jefferies analyst Maury Raycroft upgrades Tango Therapeutics (NASDAQ:TNGX) from Hold to Buy and raises the price target from $27 to $60.
- benzinga.com HC Wainwright & Co. Maintains Buy on Tango Therapeutics, Raises Price Target to $66 HC Wainwright & Co. analyst Robert Burns maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and raises the price target from $27 to $66.
benzinga.com Apple, SUNation Energy, Tango Therapeutics, Applied Digital And Cerebras Systems: Why These 5 Stocks Are On Investors' Radars Today AAPL, SUNE, TNGX, APLD, CBRS were among the stocks seen trending on Monday, June 8, 2026.- benzinga.com Tango Therapeutics Launches $500M Common Stock Offering Tango Therapeutics, Inc. ("Tango") (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced today the…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session 
benzinga.com Crude Oil Gains Over 1%; Motorcar Parts Of America Shares Surge After Q4 Earnings US stocks rose with Nasdaq up 400 points. Dow up 0.32%, Nasdaq up 1.55%, S&P 500 up 0.94%. Tech shares rose, communication services fell. Motorcar Parts of America stock jumped 37% on strong…
benzinga.com Tango Therapeutics, American Battery Technology, Intel And Other Big Stocks Moving Higher On Monday U.S. stocks higher, Nasdaq Composite up 1%. Tango Therapeutics (TNGX) shares up 34.1% on positive trial data. Other big gainers include ENHA, JLHL, ABAT, BTGO, GLXY, CLYM, SOC, SRAD, AIAI, ALOY, and…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
benzinga.com Why Is Tango Therapeutics Stock Soaring Monday? Tango Therapeutics reports 90% 6-month PFS in pancreatic cancer trial. Read about the vopimetostat combo driving TNGX stock up.- benzinga.com Tango Therapeutics Announces Initial Data From Ongoing Phase 1/2 Study Of Vopimetostat In Combination With Revolution Medicines' RAS(ON) Inhibitors In Patients With MTAP-Deleted And RAS-Mutant Metastatic PDAC Initial data from ongoing Phase 1/2 trial in patients with second and third line PDAC treated with vopimetostat and daraxonrasib showed 6-month PFS rate of 90% (median PFS not yet reached) suggesting…
benzinga.com Crude Oil Surges 3%; RBC Bearings Earnings Top Views US stocks down, S&P 500 falls 1%; Dow down 1.08%, NASDAQ down 1.42%. Energy shares up 1.5%; materials stocks down 2.1%. RBC Bearings beats Q1 estimates.- benzinga.com Mizuho Maintains Outperform on Tango Therapeutics, Raises Price Target to $30 Mizuho analyst Joseph Catanzaro maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and raises the price target from $20 to $30.
benzinga.com This Alumis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday Top analysts changed outlook on top names. See all rating changes on analyst ratings page. Check out analysts' views on ALMS stock.
benzinga.com DeFi Technologies, Babcock & Wilcox And Other Big Stocks Moving Lower In Friday's Pre-Market Session U.S. stock futures lower, Nasdaq down 1%. DeFi Technologies (DEFT) shares fell 5.3% after Q1 results. Other stocks also down in pre-market trading.- benzinga.com Piper Sandler Downgrades Tango Therapeutics to Neutral, Raises Price Target to $24 Piper Sandler analyst Kelsey Goodwin downgrades Tango Therapeutics (NASDAQ:TNGX) from Overweight to Neutral and raises the price target from $16 to $24.
benzinga.com Why Figma Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket Figma Inc (NYSE: FIG) shares rose 10.6% in pre-market trading after beating Q1 revenue and earnings estimates and raising FY26 sales guidance.- benzinga.com Jefferies Downgrades Tango Therapeutics to Hold, Raises Price Target to $27 Jefferies analyst Maury Raycroft downgrades Tango Therapeutics (NASDAQ:TNGX) from Buy to Hold and raises the price target from $18 to $27.
- benzinga.com Leerink Partners Maintains Outperform on Tango Therapeutics, Raises Price Target to $55 Leerink Partners analyst Andrew Berens maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and raises the price target from $28 to $55.
- benzinga.com Wedbush Maintains Outperform on Tango Therapeutics, Raises Price Target to $33 Wedbush analyst Robert Driscoll maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and raises the price target from $19 to $33.
benzinga.com Micron To Rally Around 42%? Here Are 10 Top Analyst Forecasts For Monday Top analysts change outlook on top names: HC Wainwright & Co. cut FEAM price target, Bernstein downgraded BF.B, Truist Securities raised RDW target, Wells Fargo upgraded WAL, Susquehanna raised MU…- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com Earnings Scheduled For March 5, 2026 
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
benzinga.com Earnings Scheduled For November 4, 2025 - benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com Earnings Scheduled For August 5, 2025